Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.9458
+0.0243 (2.64%)
At close: Jun 6, 2025, 4:00 PM
0.9300
-0.0158 (-1.67%)
Pre-market: Jun 9, 2025, 4:43 AM EDT
Silexion Therapeutics Employees
As of December 31, 2024, Silexion Therapeutics had 14 total employees, including 11 full-time and 3 part-time employees.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,174,500
Market Cap
7.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SLXN News
- 17 days ago - PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - GlobeNewsWire
- 18 days ago - Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer - GlobeNewsWire
- 26 days ago - Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - GlobeNewsWire
- 2 months ago - Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - GlobeNewsWire
- 2 months ago - Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewsWire
- 2 months ago - Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment - Business Wire